Phase 2 Breast Cancer Trial, Recruiting NCT07471776 Sponsor: Fudan University Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT07471776
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with advanced or spread (metastatic) breast cancer that is HER2-negative, whether the cancer was metastatic from the start or spread after an earlier stage.
  • People whose treating doctor has planned for them to receive a type of targeted drug treatment called an anti-TROP2 antibody-drug conjugate (such as sacituzumab govitecan or datopotamab deruxtecan) as part of their regular cancer care.
  • People who are able to undergo two specific types of body scans during the study — one using a tracer called ⁶⁸Ga-TROP2 and one using a tracer called ¹⁸F-FDG, both as part of a PET/CT scan — at the start of the study and possibly again later.
  • People aged 18 or older who are able to give informed consent and follow the study procedures.

Who may not be able to join:

  • People whose medical records are incomplete or who are unable to complete the required scans.
  • People who have previously received an anti-TROP2 antibody-drug conjugate treatment.
  • People who have a known medical reason why they cannot have a PET/CT scan, or who have a known allergy to either of the scan tracers (⁶⁸Ga-TROP2 or ¹⁸F-FDG) or their ingredients.
  • People who are pregnant or currently breastfeeding.
  • People who have another active cancer (a separate cancer diagnosis), as determined by the study doctor.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 021-64175590

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
11 March 2026
Est. completion
11 March 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Area Under the Curve (AUC) of the Imaging-Based Prediction Model

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov